MONITORING OF CONTRAST AGENT INDUCED TOXICITY IN A TERTIARY HEALTH CARE CENTRE
Keywords:
Contrast Agent, Contrast-Enhanced MRI, Contrast-Enhanced CT, Contrast-Induced Nephropathy, Gadolinium, IohexolAbstract
Background: Contrast media (CM) are used in radio-diagnostic procedures to appreciate the differences between body tissues on imaging. Therefore, monitoring the CM use and their adverse reactions is very important.
Aims and Objectives- To monitor radiological contrast agent-induced toxicity in patients and compare the toxicity and safety profile of different radiological contrast agents.
Materials and Methods: This is an open-label, prospective, observational study conducted in a tertiary care centre in April 2021 and September 2021. The study assessed the incidence of contrast-induced adverse events in radiological procedures, i.e., contrast-enhanced computerized tomography scan (CECT) and contrast-enhanced magnetic resonance imaging (CEMRI). ADRs were recorded using the standard CDSCO ADR reporting form. Causality assessment of the ADRs was done using Naranjo's scale, and severity assessment was done using modified Hartwig and Siegel scale.
Result: The distribution of patients was almost similar in both groups. The mean age of patients was not significantly different among both groups. The gender distribution of patients among the groups was almost identical. For the adverse reaction in CECT, the male-to-female ratio was 1.88, and for CEMRI, it was 1.61. The adverse drug reactions due to CEMRI and CECT were mild in severity. The results showed that adverse drug reactions between Contrast-Enhanced MRI and Contrast-Enhanced CT were not significantly different.
Conclusion: Based on the result obtained, we concluded that the contrast agents used in the radio-diagnostic procedures are safe and further research in this field is of fundamental importance.
Downloads
References
Lightfort CB, Abraham RJ, Mammen T, Abdolell M, Kapur S, Abraham KJ. Survey of radiologists- knowledge regarding the management of severe contrast material induced allergic reactions. Radiology 2009;251(3):691-96.
Thomson KR and Varma DK. Safe use of radiographic contrast media. Australian Prescriber 2010;33(1):19-22.
Violon D. Renal failure and iodinated contrast media. JBR-BTR 1999 Apr;82(2):57-62.
McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn R, et al. ContrastInduced Acute Kidney Injury. Journal of American College of Cardiology 2016;68(13).
Nyman U, Elmstahl B, Leander P, Nilsson M, Golman K, Almen T. Are Gadolinium-based Contrast Media Really Safer than Iodinated Media for Digital Subtraction Angiography in Patients with Azotemia? RSNA Radiology 2002;223(2).
Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR. American journal of Roentgenology 2001 Jun;176(6):1385-8.
Bashir U, MacManus D. Gadolinium contrast agents. RadiopaediarID: 18340; July 2012.
Thomas G. Maddox, M.D.Adverse Reactions to Contrast Material: Recognition, Prevention, and Treatment.Am Fam Physician. 2002 Oct 1;66(7):1229-1235.
Pasternak JJ and Williamson EE. Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist.Mayo Clin Proc. 2012 Apr; 87(4): 390–402.
Saljoughian M.Intravenous Radiocontrast Media: A Review of Allergic Reactions, US Pharm. 2012;37(5):HS-14-HS-16.
Andreucci M, Faga T, Serra R, De Sarro G, Michael A. Update on the renal toxicity of iodinated contrast drugs used in clinical medicine. Drug Healthc Patient Saf. 2017 May 22;9:25-37.
Bruder O, Schneider S, Nothnagel D, Pilz G, Lombardi M, Sinha A, et al. Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the EuroCMR Registry. JACC Cardiovasc Imaging. 2011 Nov;4(11):1171-6.
Stacul F. Current iodinated contrast media. EurRadiol. 2001;11(4):690-7.
Lee H, Song S, Oh YK, Kang WK, Kim E. Is gender still a predisposing factor in contrast-media associated adverse drug reactions? A systematic review and meta-analysis of randomized trials and observational studies. European Journal of Radiology 2017;89:81-89.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. ClinPharmacolTher. 1981:30(2):239-45.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J HospPharm. 1992:49(9):2229-32.
Pomara C,Pascale N,Maglietta F,Neri M,Riezzo I,Turillazzi E. Use of contrast media in diagnostic imaging: medico-legal considerations. Radiol Med 2015;120:802–809.
Kaller MO, An J. Contrast Agent Toxicity. 2021 May 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. PMID: 30725844.
Bettmann MA. Frequently Asked Questions: Iodinated Contrast Agents.RadioGraphics 2004; 24:S3–S10.
Hinson JS,Ehmann MR,Fine DM,Fishman EK,Toerper MF,Rothman RE, et al. Risk of Acute Kidney Injury After Intravenous Contrast Media Administration. Annals of emergency medicine2017 May;69(5):577-586.
Aycock RD,Westafer LM,Boxen JL,Majlesi N,Schoenfeld EM,Bannuru RR. Acute Kidney Injury After Computed Tomography: A Meta-analysis. Annals of emergency medicine2018 Jan;71(1):44-53.
Spampinato MV, Abid A, Matheus MG. Current Radiographic Iodinated Contrast Agents. MagnReson Imaging Clin N Am 2017;25:697-704.
Cha MJ, Kang DY, Lee W, Yoon SH,Choi YH, Byun JS. Hypersensitivity Reactions to Iodinated Contrast Media: A Multicenter Study of 196081 Patients. Radiology 2019; 293:117–124.
Pelagatti V, Bagheri H,Fernandez P,Railhac N, Bregeon C, Railhac JJ, et al. Adverseeffects of contrast media: results of a 6 months study. Therapies 2000;55(3):391-4.
Prince MR, Zhang H, Zou Z, Staron RB and Brill PW. Incidence of Immediate Gadolinium Contrast Media Reactions. JR Am J Roentgen. 2011 Feb;196(2):138-43.
Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR. American journal of roentgenology 2009 Oct;193(4):1124-7.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Mantasha Rehmani, Irfan Ahmad Khan
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.